Passa al contenuto
Merck
Tutte le immagini(1)

Key Documents

Altri documenti

Y0000598

Medroxyprogesterone acetate for system suitability

European Pharmacopoeia (EP) Reference Standard

Sinonimo/i:

Medroxyprogesterone 17-acetate, 17α-Acetoxy-6α-methylprogesterone, 17α-Hydroxy-6α-methyl-4-pregnene-3,20-dione 17-acetate, 6α-Methyl-17α-acetoxyprogesterone, 6α-Methyl-17α-hydroxyprogesterone acetate

Autenticatiper visualizzare i prezzi riservati alla tua organizzazione & contrattuali
Tutte le immagini(1)

About This Item

Formula empirica (notazione di Hill):
C24H34O4
Numero CAS:
71-58-9
Peso molecolare:
386.52
Beilstein:
2066112
Numero MDL:
MFCD00010483
Codice UNSPSC:
41116107
ID PubChem:
329831042
NACRES:
NA.24

Grado

pharmaceutical primary standard

Famiglia di API

medroxyprogesterone

Produttore/marchio commerciale

EDQM

Punto di fusione

206-207 °C (lit.)

applicazioni

pharmaceutical (small molecule)

Formato

neat

Stringa SMILE

[H][C@@]12C[C@H](C)C3=CC(=O)CC[C@]3(C)[C@@]1([H])CC[C@@]4(C)[C@@]2([H])CC[C@]4(OC(C)=O)C(C)=O

InChI

1S/C24H34O4/c1-14-12-18-19(22(4)9-6-17(27)13-21(14)22)7-10-23(5)20(18)8-11-24(23,15(2)25)28-16(3)26/h13-14,18-20H,6-12H2,1-5H3/t14-,18+,19-,20-,22+,23-,24-/m0/s1
PSGAAPLEWMOORI-PEINSRQWSA-N

Informazioni sul gene

human ... PGR(5241)

Cerchi prodotti simili? Visita Guida al confronto tra prodotti

Categorie correlate

Descrizione generale

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the Issuing Pharmacopoeia. For further information and support please go to the website of the issuing Pharmacopoeia.

Applicazioni

Medroxyprogesterone acetate for system suitability EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.

Confezionamento

The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.

Altre note

Sales restrictions may apply.

Prodotti correlati

N° Catalogo
Descrizione
Determinazione del prezzo

1378001

Medroxyprogesterone acetate, United States Pharmacopeia (USP) Reference Standard

1378012

Medroxyprogesterone acetate Related Compound A, United States Pharmacopeia (USP) Reference Standard

M0250000

Medroxyprogesterone acetate, European Pharmacopoeia (EP) Reference Standard

Y0001484

Medroxyprogesterone acetate for peak identification, European Pharmacopoeia (EP) Reference Standard

PHR1589

Medroxyprogesterone Acetate, Pharmaceutical Secondary Standard; Certified Reference Material

1378023

Medroxyprogesterone acetate Related Compound B, United States Pharmacopeia (USP) Reference Standard

BP221

Medroxyprogesterone acetate, British Pharmacopoeia (BP) Reference Standard

Pittogrammi

Health hazard
GHS08

Avvertenze

Warning

Indicazioni di pericolo

H351 - H413

Classi di pericolo

Aquatic Chronic 4 - Carc. 2

Codice della classe di stoccaggio

11 - Combustible Solids

Classe di pericolosità dell'acqua (WGK)

WGK 3

Scegli una delle versioni più recenti:

Certificati d'analisi (COA)

Lot/Batch Number

Ci dispiace, ma al momento non ci sono COA disponibili online per questo prodotto.

Se ti serve aiuto, non esitare a contattarci Servizio Clienti

Possiedi già questo prodotto?

I documenti relativi ai prodotti acquistati recentemente sono disponibili nell’Archivio dei documenti.

Visita l’Archivio dei documenti

Léanie Kleynhans et al.
Infection and immunity, 81(4), 1234-1244 (2013-02-06)
The contraceptive depot medroxyprogesterone acetate (DMPA), with progestin as the single active compound, possesses selective glucocorticoid activity and can alter the expression of glucocorticoid receptor-regulated genes. We therefore propose that pharmacological doses of DMPA used for endocrine therapy could have
Lee L Lanza et al.
Obstetrics and gynecology, 121(3), 593-600 (2013-05-03)
Depot medroxyprogesterone acetate (DMPA) reversibly reduces bone mineral density. To estimate the extent to which DMPA might increase fracture risk, we undertook a retrospective cohort study of fractures in DMPA users and users of non-DMPA contraceptives, using the General Practice
Robert A Wild et al.
Menopause (New York, N.Y.), 20(3), 254-260 (2013-02-26)
Our objective was to determine whether metabolic syndrome (MetS) or its components modified the effect of hormone therapy (HT) on the risk of coronary heart disease (CHD) events in the Women's Health Initiative clinical trials. We performed a nested case-control
Richard P H Huijbregts et al.
Endocrinology, 154(3), 1282-1295 (2013-01-29)
Recent observational studies indicate an association between the use of hormonal contraceptives and acquisition and transmission of HIV-1. The biological and immunological mechanisms underlying the observed association are unknown. Depot medroxyprogesterone acetate (DMPA) is a progestin-only injectable contraceptive that is
JoAnn E Manson et al.
JAMA, 310(13), 1353-1368 (2013-10-03)
Menopausal hormone therapy continues in clinical use but questions remain regarding its risks and benefits for chronic disease prevention. To report a comprehensive, integrated overview of findings from the 2 Women's Health Initiative (WHI) hormone therapy trials with extended postintervention
Visualizza tutti i documenti correlati

Il team dei nostri ricercatori vanta grande esperienza in tutte le aree della ricerca quali Life Science, scienza dei materiali, sintesi chimica, cromatografia, discipline analitiche, ecc..

Contatta l'Assistenza Tecnica.